Essayer OR - Gratuit
PlasmaGen secures ₹150 cr to expand into global markets
Mint Chennai
|December 23, 2025
Biopharmaceutical company PlasmaGen Biosciences raised ₹150 crore in a new round of equity financing, valuing the firm at more than ₹1,500 crore.
ViNS Bioproducts, a specialty biopharma company, picked up a minority equity stake in PlasmaGen and led the round with participation from existing investors and other pharma companies and family offices.
PlasmaGen will use the new funds to take its business international. The company has identified distribution partners in “key” export markets.
Back home, the company plans to double down on its presence with its current portfolio of plasma-derived therapeutics. The company’s key products include albumin, intravenous immunoglobulin, rabies immunoglobulin, hepatitis B immunoglobulin, and RhD immunoglobulin (anti-D) which it distributes to private hospitals and state hospitals in India.
Cette histoire est tirée de l'édition December 23, 2025 de Mint Chennai.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Mint Chennai
Mint Chennai
Simple Energy looks to raise $30-40 mn
Electric two-wheeler maker Simple Energy plans to raise $30-40 million in fresh capital, largely from international backers and existing investors, in what could be its first round with institutional participation, chief executive Suhas Rajkumar told Mint. So far, the company has raised capital mainly from family offices and high net worth individuals rather than venture capital funds.
1 min
January 06, 2026
Mint Chennai
How to make your middle years count
Begin to view your 40s and 50s as the start of a new innings
2 mins
January 06, 2026
Mint Chennai
Training the mind for greater endurance
From summiting peaks to living with chronic illness, five intrepid individuals share mental strategies that help them push past their limits
5 mins
January 06, 2026
Mint Chennai
The year Indian drug innovation bets started paying off
In July, Mumbai-headquartered Glenmark grabbed the spotlight when it signed what was one of the biggest out licensing deals for an Indian drug-maker with Chicago-based AbbVie Inc. for an underdevelopment cancer drug.
4 mins
January 06, 2026
Mint Chennai
AI-POWERED SCAMS: A NEW ONSLAUGHT YOU CAN'T IGNORE
Across India, families are quietly absorbing losses to digital fraud.
3 mins
January 06, 2026
Mint Chennai
Trump warns of higher India tariffs
Graham, a close Trump ally travelling with him, said US sanctions on Russian oil companies and higher tariffs on India had helped curb Indian oil imports.
1 min
January 06, 2026
Mint Chennai
Trump waves the tariff card again
The United States could raise tariffs on India if New Delhi does not meet Washington's demand to curb purchases of Russian oil, president Donald Trump said on Sunday, escalating pressure on the South Asian country as trade talks remain inconclusive.
1 min
January 06, 2026
Mint Chennai
Buckle up: Turbulence in the East seems set to rise this year
East Asia will probably become more volatile as tensions deepen
3 mins
January 06, 2026
Mint Chennai
Race to save brand, celebrity identity will intensify in 2026
The courtroom scramble is expected to make way for deliberate, proactive action this year
3 mins
January 06, 2026
Mint Chennai
Can we put AI to work in aid of inclusive growth?
Plans are in place for artificial intelligence to lift our path of economic expansion and put 'developed country' status within reach. The bigger challenge is to ensure that everyone gains
2 mins
January 06, 2026
Listen
Translate
Change font size